Hall Christopher M sold $1.3M of PSNL

Personalis (Nasdaq: PSNL) reported Q2 2026 results for the quarter ended June 30. Clinical tests rose 199% to 10,384. Clinical revenue increased 442% to $2.6 million, while total revenue grew 30% to $22.4 million. The company said it secured Medicare coverage for NeXT Personal in additional IO and neoadjuvant breast cancer indications and ended the quarter with about $212.7 million in cash.

Personalis, Inc. (PSNL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 psnl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Personalis Reports Second Quarter Results and Recent Highlights Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

Tempus AI (TEM) agreed to acquire Personalis (PSNL) for about $1.5 billion, paying $16.25 per Personalis share including debt. The deal gives Tempus full control of the NeXT Personal MRD cancer test. Personalis reported preliminary Q2 revenue of $22.4 million. Tempus stock fell about 9% on July 20 amid expected dilution and delayed closing to late 2026/early 2027.

Tempus AI (NASDAQ:TEM) agreed to acquire Personalis (NASDAQ:PSNL) for $1.5 billion to expand minimal residual disease (MRD) capabilities. Tempus shares recovered after an early selloff. William Blair sees strategic fit and a $20 billion MRD market, but notes a high ~14x 2027 sales multiple and Personalis’ expected 2027 adjusted EBITDA loss of about $90 million. BNP Paribas said the deal could increase pressure on Natera (NASDAQ:NTRA).

Tempus AI shares swung after an early selloff tied to its $1.5 billion acquisition of Personalis, which Tempus says targets a $20 billion MRD market. William Blair views the strategic fit positively but flags profitability, citing Personalis adjusted EBITDA of about -$90M for 2027. Tempus aims for EBITDA and FCF positive in 2027. TEM was up 1.96% to $49.36.